OTLK News and Press, Outlook Therapeutics Inc.

2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-08 10:03:19 ET More on Outlook Therapeutics Outlook Therapeutics: Worth A Good Strong Look After CRL Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript Outl...

UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...

2024-06-25 07:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding undervalued stocks to buy may greatly improve an investing portfolio’s ability to capture enormous long-term profits. This piece examines three inexpensive yet pote...

2024-06-13 17:22:01 ET Summary Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to conduct an additional clinical trial for ONS-5010. ...

2024-06-13 05:50:39 ET Summary Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024, and it is preparing for a commercial launch in e...

Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...

2024-05-28 11:50:44 ET More on Outlook Therapeutics Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval Outlook Therapeutics shares rise after 'buy' rating f...

LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...

2024-05-16 14:35:26 ET Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Kenyon - Chief Financial Officer Conferen...